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Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different approaches and antibody
formats are being investigated for the ability to neutralize animal toxins. These different molecular
formats each have their own therapeutic characteristics. In this review, we provide an overview of the
advances made in the development of toxin-targeting antibodies, and discuss the benefits and draw-
backs of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic
features, propensity to cause adverse reactions, formulation, and expression for research and develop-
ment (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the
use of human antibody formats as well as camelid heavy-domain antibody fragments due to their
compatibility with the human immune system, beneficial therapeutic properties, and the ability to
manufacture these molecules cost-effectively.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The world fauna presents a vast variety of venomous animals
including snakes, scorpions, spiders, bees, wasps, caterpillars, sea
anemones, jellyfishes, lizards, fishes, and cone snails as examples.r Ltd. This is an open access articleMany of these animals can cause severe envenomings by their sting
or bite, inflicting pain, tissue damage, and systemic pathologies,
and may in some cases cause fatalities. The true number of these
accidents is unknown, as even the World Health Organization
(WHO) does not report epidemiological data for envenomings by all
classes of venomous animals. However, it has been estimated that
snakes alone cause 1.8 to 2.7 million envenomings each year,
resulting in 81,000 to 138,000 deaths (Gutierrez et al., 2017a), while
scorpion stings result in 1.2 million envenomings per year, leadingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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snakebite envenoming is classified by the WHO as a Neglected
Tropical Disease (NTD), a group of diseases that prevail in tropical
and subtropical parts of the world and mainly affect populations
living in poverty with very limited access to healthcare.
The specific medical treatment for envenomings caused by an-
imals is the use of antivenoms. Heterologous antivenom serother-
apy is a century-old treatment described simultaneously by Cesaire
Auguste Phisalix, Gabriel Bertrand, and Albert Calmette in France in
1894 (Calmette, 1894; Phisalix and Bertrand, 1894). Later (1901), in
Brazil, Vital Brazil Mineiro da Campanha demonstrated that anti-
venom specificity is essential for treating envenomings from
particular species (Hawgood, 1992). Since that time, the use of
antivenoms has saved countless lives. Nowadays, different heter-
ologous antivenoms are manufactured in many countries with the
aim of neutralizing venoms from diverse venomous animal species
(Laustsen et al., 2016a). Supplies of these life-saving medicines are,
however, still critically scarce in many regions (Brown and Landon,
2010), and efforts are being carried out to improve their availability
and accessibility (Gutierrez, 2012).
Although heterologous antivenoms are, to this date, the only
effective treatment for snakebite envenomings, these therapeutic
agents present some documented undesirable problems (Fig. 1): (i)
Antivenoms can cause anaphylactic reactions, which can be either
IgE-mediated or, more commonly, non-IgE-mediated (due to
complement activation); both types are known as early adverse
reactions (up to 24 h) (de Silva et al., 2011; Isbister et al., 2008a,b;
Leon et al., 2013). (ii) Antivenoms are composed of whole immu-
noglobulins (IgGs) or antigen-binding fragments (F(ab')2s or Fabs)
raised against whole venom(s) via immunization of a host animal
(Laustsen et al., 2016a, 2016c; Rodríguez-Rodríguez et al., 2016).
However, the majority of these antibodies are not directed towards
medically relevant venom toxins (Laustsen et al., 2015), but are
instead directed against antigens that the immunized animal has
encountered during its life (environmental antigens, microorgan-
isms, and parasites). As a consequence, most antivenoms carry a
large portion of immunoglobulins that are not directed against
venom components (about 70%) (Laustsen et al., 2016a; Segura
et al., 2013). (iii) The large amount of antivenom antibodies com-
bined with the elicited human anti-horse antibodies (IgGs and
IgMs) may result in the generation of immune complexes (ICs) that
have a long elimination half-life. This can trigger IC deposition in
target tissues (such as blood vessels, glomeruli, and joints), medi-
ating inflammation and promoting serum sickness e a late adverse
reaction associated with type III hypersensitivity (1e2 weeks after
antivenom therapy) (Cunningham et al., 1987; Descotes and
Choquet-Kastylevsky, 2001).
Taken together with the high cost of antivenom production,
which is dependent on both animal immune systems and pro-
curement of venoms, a need for innovation within envenoming
therapies exists. Several approaches, including the use of immu-
nization with DNA, synthetic epitope strings, or recombinant
toxins, have been pursued (Alvarenga et al., 2002; Araujo et al.,
2003; Harrison, 2004; Laustsen et al., 2016a, 2016c). However,
despite a promising potential for eliminating the need for keeping
venomous animals in captivity and “milking” them to obtain their
venoms, these novel immunization techniques all retain the
drawbacks of creating heterologous antivenomswith compromised
compatibility with the human immune system. A more recent
avenue that has been taken is the development of recombinant
antibodies and antibody fragments of camelid and/or human origin
(Harrison et al., 2011; Laustsen et al., 2016a, 2016c; Pucca et al.,
2012; Pucca et al., 2011a,b; Richard et al., 2013). These molecules
have very low immunogenicity and are easy to engineer usingstandard approaches that are well-investigated in other fields. This
allows for the design of more optimized envenoming therapies
with better safety profiles and potentially higher efficacy, as such
recombinant antibodies would be completely compatible with the
human immune system. Furthermore, only therapeutically active
antibodies targetingmedically relevant toxins would be included in
a novel recombinant antivenom (Laustsen et al., 2015). Addition-
ally, in the future it is projected that the production of recombinant
antivenoms based on mixtures of such antibodies may be cost-
effective compared to traditional antivenom manufacturing
methods (Laustsen et al., 2017, 2016b). However, although several
antibody formats have been investigated for use in recombinant
antivenoms (Fig. 2), a clear indication of which format represents
the optimal molecular scaffold to be used does not exist. In this
review, we therefore aim at presenting all available data on
different antibody formats that have been investigated for
neutralization of animal toxins, and discuss their pros and cons in
relation to toxin targeting in clinical scenarios.2. Pharmacodynamics: ability to neutralize venom toxins
Pharmacodynamics (PD) plays a key role in the successful
outcome of antivenom immunotherapy. Within the field of anti-
venom, PD refers to the ability of therapeutic molecules to
neutralize in vivo specific venom toxins present in a given venom,
which is one of the key determinants of antivenom efficacy. Inde-
pendent of their antibody format, antivenoms derive their PD ef-
ficacy from high affinity interactions between each antibody-toxin
pair, although antibody stability is also considered important for
neutralization capacity (Juarez-Gonzalez et al., 2005). In the simple
situation involving only a single antibody and a single toxin, affinity
is often reported using the dissociation constant, Kd. However,
several factors complicate such measurements when comparing
classical polyclonal antivenoms: (i) several different antivenom
antibodies (with different specificities) may recognize the same or
various epitopes in a single toxin; (ii) each individual antivenom
antibody may recognize similar (homologous) toxins with different
affinities; (iii) the concentration of each antibody that recognizes a
given toxin is unknown. For these reasons, it is only feasible to
measure the avidity (a measure of the strength between a venom
and multiple antibodies), also interpreted as functional affinity
(Casewell et al., 2010; Vauquelin and Charlton, 2013). To our
knowledge, no studies have systematically investigated the effect
on avidity after enzymatic treatment of polyclonal IgGs to Fabs (or
F(ab')2s). However, one may expect a higher avidity of an IgG or
F(ab')2-based antivenom than a Fab-based antivenom due to the
bivalent nature of the IgG and F(ab')2 formats. The two independent
binding sites on these antibody formats provide a larger probability
that a toxin will become rebound to the antibody if the toxin is
released due to molecular proximity effects. Additionally, cross-
linking to other toxin-antibody complexes can take place, making
it less likely that a toxin may escape during transient dissociation of
the complex (Rudnick and Adams, 2009). This cross-linking effect
may potentially lead to high therapeutic relevance of weaker in-
teractions. Nevertheless, at least one Fab-based antivenom has
proven to be at least as effective in the clinical setting than an IgG-
based antivenom (Dart and McNally, 2001).
Monoclonal IgGs and single-chain variable fragments (scFvs) are
the primary recombinant antibody formats that have been inves-
tigated for neutralization of animal toxins. In vivo lethality studies
assessing the neutralization capacity of several monoclonal IgGs
have shown positive results for snake toxins (Charpentier et al.,
1990; Frauches et al., 2013; Stiles et al., 1994), spider toxins
(Alvarenga et al., 2003; Boulain et al., 1982), and scorpion toxins
Fig. 1. Disadvantages of current animal plasma-derived antivenoms. Early adverse reactions occur within 24 h after administration of antivenoms. (A1) Patients may develop
early adverse reactions (within 24 h) resulting from de novo complement activation (non-IgE reactions) or, (A2) in cases of previous exposure to animal antibodies, due to IgE-
mediated anaphylactic reactions. (B) Around 70% or more of the antivenom antibodies are not directed towards medically relevant venom toxins. Therefore, envenomed vic-
tims will receive a larger than necessary dose of equine antibodies, which have no therapeutic value, but which may cause adverse reactions. (C) The large amount of antivenom
antibodies combined with elicited human anti-horse antibodies (IgGs and IgMs) may result in overproduction of immune complexes. These may be deposited in blood vessels,
glomeruli, and joints, mediating inflammation and promoting serum sickness 1e2 weeks after administration of antivenom therapy. Black antibodies: equine antibodies specific to
target toxins. Red antibodies: equine antibodies against non-venom antigens. Blue antibodies: human antibodies against equine antibodies. Green circles: Snake toxins. For the
sake of simplicity, examples illustrating the disadvantages of heterologous antibody therapy refer to equine antivenoms, but the same principles apply to antivenoms derived from
other animal species. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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1992) as summarized in Tables 1e3, respectively. Studies testing
neutralization through biochemical assays have additionally found
promising results against both snake toxins (Boulain et al., 1982;
Charpentier et al., 1990; Tremeau et al., 1986) and scorpion toxins
(Alvarenga et al., 2005) for the IgG format. In addition, many studies
focusing on snake venom toxins have discovered IgGs with
neutralizing abilities againstmultiple specific toxins responsible for
myonecrosis (Frauches et al., 2013; Li et al., 1993; Lomonte et al.,
1992; Lomonte and Kahan, 1988), hemorrhage (Fernandes et al.,
2010; Frauches et al., 2013; Iddon et al., 1988; Morine et al., 2008;
Perez et al., 1984; Schneider et al., 2014; Tanjoni et al., 2003b), andproteolytic effects (Morine et al., 2008; Schneider et al., 2014), as
shown in Table 1.
Another of the most commonly investigated antibody formats
is the Fab format. Two different studies produced Fabs against
snake toxins. In one study, a Fab targeting cardiotoxin from Naja
nigricollis venom was developed (Guillon et al., 1986), and in
another study a Fab was developed against b1-bungarotoxin from
Bungarus multicinctus venom (Yang and Chan, 1999). Both Fabs
were shown to neutralize in vitro and in vivo effects of the toxins,
respectively. Four studies have developed monoclonal Fabs against
spider and scorpion toxins. Of these, three exhibited neutralizing
effects in vivo against spider toxins (Bugli et al., 2008) and
Fig. 2. Schematic overview of the different antibody formats used in existing plasma-derived antivenoms and experimental recombinant antivenoms. IgG: whole IgG
antibody. F(ab’)2: pepsin-digested IgG antigen-specific region. Fab: papain-digested antigen-specific region. Diabody: non-covalent dimers of scFv fragments. scFv: single-chain
variable fragments. VHH: single-domain antigen-specific fragments.
Table 1
Reported monoclonal antibodies and antibody fragments against snake venom toxins.
Antibody format Snake Toxin Origin Kd (nM) Therapeutic effects Ref.
Myotoxic
effects
Haemotoxic
effects
Biochemical
assay
Lethality
IgG1 Echis carinatus Whole venom Murine In vivo (Iddon et al., 1988)
IgG2a, IgG2b Naja naja oxiana Neurotoxin I Murine In vivo (Stiles et al., 1994)
IgM, IgG1,
IgG2b
Bothrops asper BaP1 Murine In the nM range In vivo (Fernandes et al., 2010)
IgG Naja naja siamensis a-cobratoxin Murine Estimated
at 2.1e3.7
In vitro (Charpentier et al., 1990)
IgG1, IgM Bothrops atrox Atroxlysin-I Murine 8.52e15.10 In vivo (Schneider et al., 2014)
IgG Bothrops atrox Murine In vivo In vivo In vivo (Frauches et al., 2013)
IgG2a Naja nigricollis,
Laticauda semifasciata,
Laticauda colubrina,
Naja mossambica and
Naja naja atra
Toxin a,
Erabutoxin b and c,
Toxin d,
Toxin I and III and
Cobrotoxin
Murine 2e1.500 In vitro (Tremeau et al., 1986)
IgG1 Bothrops jararaca Jarahagin Murine In vivo (Tanjoni et al., 2003b)
IgG1 Agkistrodon contortrix
lacticinctus
Myotoxin Murine In vivo (Li et al., 1993)
IgG Crotalus atrox Murine In vivo (Perez et al., 1984)
IgG2a Naja nigricollis Toxin a Murine 0.35 In vitro In vivo (Boulain et al., 1982)
IgG1, IgM Bothrops asper Myotoxin Murine In vivo (Lomonte and
Kahan, 1988)
IgG1 Probothrops flavoviridis HR1a Human In vivo (Morine et al., 2008)
scFv Crotalus durissus terrificus Crotoxin Murine 0.2e7.4 In vivo (Meng et al., 1995)
scFv Crotalus durissus terrificus Subunit B
Crotoxin (II-PLA2)
Human 10,000 (Lafaye et al., 1997)
scFv Naja kaouthia Long alfa
neurotoxin
Human In vivo (Kulkeaw et al., 2009)
scFv Bothrops asper BaP1 Not specified In vivo In vivo (Castro et al., 2014)
scFv Vipera ammodytes
meridionalis
Vipoxin (PLA2) Human In vitro (Stoyanova et al., 2012)
scFv Bothrops jararacussu All the PLA2
isoforms of
the venom
Human In vivo In vivo (Roncolato et al., 2013)
scFv Bothrops jararacussu BthTXI and
BthTX-II PLA2
Human In vivo (Tamarozzi et al., 2006)
scFv Crotalus durissus terrificus Subunit B
Crotoxin (II-PLA2)
Human In vivo In vivo (Oliveira et al., 2009)
scFv Crotalus durissus terrificus Crotoxin Human In vivo (Cardoso et al., 2000)
VHH Naja kaouthia a-cobratoxin Camelid 2.0e3.0 (Stewart et al., 2007)
VHH/IgG Naja kaouthia a-cobratoxin Camelid 0.4e25 In vivo (Richard et al., 2013)
VH/VHH Naja kaouthia PLA2 Camelid In vitro (Chavanayarn
et al., 2012)
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the last study did not obtain neutralizing Fab antibodies (Aubrey
et al., 2004). As previously mentioned, the scFv antibody format
has also been widely studied. scFvs showing neutralization of
lethality in vivo have been reported for both snake toxins (Cardoso
et al., 2000; Castro et al., 2014; Kulkeaw et al., 2009; Lee et al.,
2015; Meng et al., 1995; Oliveira et al., 2009; Roncolato et al.,2013) and scorpion toxins (Amaro et al., 2011; Devaux et al.,
2001a; Hmila et al., 2012; Mousli et al., 1999; Ria~no-Umbarila
et al., 2016, 2013, 2011, 2005; Rodríguez-Rodríguez et al., 2016).
To obtain more biochemical details regarding scorpion toxin
neutralizing capacity, electrophysiological studies involving the
two-electrode voltage clamp technique using Xenopus laevis frog
oocytes showed that activation of sodium channels by Tityus
Table 2
Reported monoclonal antibodies and antibody fragments against spider venom toxins.
Antibody format Spider Toxin Origin Therapeutic effects Reference
Lethality
IgG Loxosceles intermedia unknown Murine (Alvarenga et al., 2003)
Fab Latrodectus tredecimguttatus a-latrotoxin Murine In vivo (Bugli et al., 2008)
IgG Loxosceles intermedia SmaseD Murine In vivo (Dias-Lopes et al., 2014)
Table 3
Reported monoclonal antibodies and antibody fragments against scorpion venom toxins.
Antibody format Scorpion Toxin Origin Kd (nM) Therapeutic effects Reference
Biochemical assay Lethality Not
neutralizing
IgG Androctonus australis AahII Murine 0.8 In vivo (Bahraoui et al., 1988)
IgG1, IgG2a, IgG2b Androctonus australis hector AahI Murine In vivo (Clot-Faybesse et al., 1999)
IgG Buthus martensi BmK AS-1 Murine 0.0278-
0.152
(Jia et al., 2000)
IgG2a, IgG1 Centruroides noxius Cn2 Murine In vivo (Zamudio et al., 1992)
IgG1 Tityus serrulatus Murine In vitro (Alvarenga et al., 2005)
Fab Androctonus australis AahI Murine 0.082 x (Aubrey et al., 2004)
Fab Centruroides noxius Cn2 Murine In vivo (Selisko et al., 2004)
Fab Centruroides noxius Cn2 Murine In vivo (Licea et al., 1996)
scFv Androctonus australis AahII Murine In vivo (Mousli et al., 1999)
scFv Androctonus australis AahI Murine In vivo (Devaux et al., 2001b)
scFv Centruroides noxius Cn2 Human 1.01 In vivo (Ria~no-Umbarila et al., 2005)
scFv Centruroides noxius Cn2 Murine 0.075 x (Juarez-Gonzalez et al., 2005)
scFv Centruroides noxius and
Centruroides suffusus suffusus
Cn2 and Css2 Human 0.05e16.60 In vivo (Ria~no-Umbarila et al., 2011)
scFv Centruroides suffuses,
Centruroides limpidus,
Centruroides noxius and
Centruroides tecomanus
Css2, Css4,
Cll1, Cll2,
Cn2,
Ct1a
Human 1e290 In vivo (Rodríguez-Rodríguez et al., 2016)
scFv Centruroides noxius and
Centruroides limpidus limpidus
Cll1 and Cn2 Human 8.1e25.1 In vivo (Ria~no-Umbarila et al., 2013)
scFv Centruroides noxius. Cn2 Human 5.4e93.7 In vivo (Ria~no-Umbarila et al., 2016)
scFv Tityus serrulatus Ts1 Human In vivo (Amaro et al., 2011)
scFv Tityus serrulatus Whole venom Human (Pucca et al., 2012)
scFv Tityus serrulatus Ts1 and Ts2 Human In vitro (Pucca et al., 2014)
VHH Androctonus australis AahI Camelid 1.21e55.8 In vivo (Hmila et al., 2008)
VHH Androctonus australis AahII Camelid 0.12e76.00 In vivo (Abderrazek et al., 2009)
VHH Androctonus australis AahI and AahII Camelid In vivo (Hmila et al., 2010)
VHH Androctonus australis AahI and AahII Camelid In vivo (Hmila et al., 2012)
Diabody mixture Androctonus australis AahI and AahII Murine In vivo (di Tommaso et al., 2012)
Diabody Centruroides noxius Cn2 Human 0.0369e0.095 In vivo (Rodríguez-Rodríguez et al., 2012)
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human scFvs (Pucca et al., 2014). Also, scFvs capable of neutral-
izing myonecrosis have been reported for snake venom toxins
(Oliveira et al., 2009; Roncolato et al., 2013; Tamarozzi et al.,
2006). Other scFvs have been discovered, which can neutralize
melittin and phospholipase A2 (PLA2) from Africanized bees
in vitro and prolong survival in vivo (see Table 4). However, scFvs
that lack neutralizing abilities have also been reported (Juarez-
Gonzalez et al., 2005). In addition to assessing their neutraliza-
tion potential, a few studies of scFv antibodies developed against
snake venom toxins also include a structural and sequencing
analysis to determine the regions involved in toxin binding
(Kulkeaw et al., 2009; Lafaye et al., 1997; Meng et al., 1995).
Several studies have involved two other small antibody formats,
variable fragments of heavy chain antibodies (VHHs) and dimers of
scFvs (diabodies), used against snake and scorpion toxins. Of these,
one VHH has shown neutralization of lethality against snake toxins
(Richard et al., 2013), whereas both VHHs (Abderrazek et al., 2009;
Hmila et al., 2012, 2008, 2008) and diabodies (di Tommaso et al.,
2012; Rodríguez-Rodríguez et al., 2012) have shown neutraliza-
tion of lethality against scorpion toxins. For IgGs (Bahraoui et al.,
1988; Boulain et al., 1982; Charpentier et al., 1990; Fernandeset al., 2010; Iddon et al., 1988; Jia et al., 2000; Schneider et al.,
2014; Tremeau et al., 1986), Fabs (Aubrey et al., 2004), scFvs
(Juarez-Gonzalez et al., 2005; Lafaye et al., 1997; Lee et al., 2015;
Meng et al., 1995; Ria~no-Umbarila et al., 2016, 2013, 2011, 2005;
Rodríguez-Rodríguez et al., 2016), and VHHs (Abderrazek et al.,
2009; Hmila et al., 2008; Richard et al., 2013; Stewart et al., 2007)
some studies have determined the Kd between the antibodies and
their respective toxins. The Kds range from 10 mM as the highest
reported for an scFv against crotoxin from the venom of the South
American rattlesnake (Lafaye et al., 1997) to the lowest Kd of 28 pM
for an IgG developed against BmK AS-1 from the Chinese scorpion
Buthus martensii Karsch (Jia et al., 2000). The reported Kds seem to
corroborate the notion that high affinity frequently correlates with
better neutralization ability, where antibodies with neutralizing
abilities have Kds in the lower nanomolar range, as shown in
Tables 1 and 3.
All reported monoclonal antibody formats that have been
developed against snake, scorpion, spider, and bee venom toxins
seem to neutralize toxins equally well (see Tables 1e4). No
conclusion can thus be drawn on which format binds and neu-
tralizes animal toxins best. However, one major challenge when
comparing different antibody formats is that studies have
Table 4
Reported monoclonal antibodies and antibody fragments against bee venom toxins.
Antibody format Bee Toxin Origin Therapeutic effects Reference
Myotoxic effects Hemotoxic effects Lethality
scFv Apis mellifera Mellitin and PLA2 Murine In vivo In vivo (Santos et al., 2013)
scFv Apis mellifera Mellitin and PLA2 Human In vivo (Funayama et al., 2012; Pessenda et al., 2016)
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zation. For better comparison of neutralization potentials of
different antibodies, it would be beneficial if a common approach
could be employed, such as that recommended by the WHO for
assessing the preclinical efficacy of antivenoms. Following this
approach, in vivo neutralization is assessed by pre-incubation of
toxin and antibody prior to injection into rodents, as this has been
shown to yield the best reproducibility of results and allow for
better comparability between antivenoms (Gutierrez et al., 2017b).
This protocol does, however, not mimic a real life envenoming and
subsequent treatment scenario, and antibodies showing neutrali-
zation potential when pre-incubated with the toxin prior to injec-
tion may not show efficacy if administered after venom injection
(Charpentier et al., 1990). It would therefore be more relevant to
evaluate antivenom neutralizing capacity in experiments involving
independent administration of venoms and antibodies, i.e. ‘rescue
experiments’. Overall and unsurprisingly, no final conclusion can be
drawn based purely on pharmacodynamics regarding which anti-
body format represents the most optimal format for toxin
neutralization. To allow for better comparison between different
antibody formats it would be beneficial to test a single monoclonal
antibody and its derived formats against the same toxin target. In
this context, no prior studies have been performed within the field
of toxinology.2.1. Modes of neutralization
Understanding the modes of neutralization of antibodies may
guide the design of novel antivenom components. Nonetheless,
only limited efforts have been invested in this area, and it is
therefore not possible to determine any general trend in how
different antibody formats neutralize various animal toxins. How-
ever, studies of single antibodies targeting mainly snake venom
toxins have proposed five different mechanisms to explain the
mode of neutralization. Firstly, direct inhibition where antibodies
interfere with the site of interaction between the toxin and its
target by competitive inhibition (Fig. 3A). This mechanism has been
demonstrated for an anti-long chain neurotoxin monoclonal anti-
body (Charpentier et al., 1990) and has been suggested as a general
mode of neutralization of small neurotoxins by polyvalent anti-
venoms (Engmark et al., 2017a, 2016). Secondly, for enzymatic
toxins, direct inhibition may be equivalent to blocking the catalytic
site (Fig. 3B). Similar to direct inhibition, binding of a relative large
antibody (fragment) to a region near the site of interaction may
result in a steric hindrance effect (Fig. 3C). However, to the best of
our knowledge no record of such situation is available, although it is
structurally feasible. A third mechanism is allosteric inhibition
(Fig. 4), where binding of the antibody induces a conformational
change making a toxic site inaccessible or locking the toxin in a
much less toxic, or even inactive, conformation. As an example, a
polyvalent Crotalinae antivenom has been reported to recognize
linear peptides mimicking a known allosteric site from snake
venom serine proteases (Engmark et al., 2017b). Fourthly, anti-
bodies can prevent the dissociation of toxin complexes responsible
for forming the active toxins (Lafaye et al., 1997) (Fig. 5). Fifthly,even if an antibody does not block the active site of the toxin nor an
allosteric site, the formation of toxin-antibody complexes may
preclude the toxin from interacting with its target, and may facil-
itate its elimination by the mononuclear phagocytic system
(Gutierrez and Leon, 2009).
On the more general level of venom toxicity, neutralization of
single toxins by antibodies may reduce the clinical manifestations
dramatically. This may be explained by high individual toxicity and/
or high concentration of a single toxin in a venom (Laustsen et al.,
2015), and when this toxin is neutralized, only weakly toxic or non-
toxic components remain. However, abrogation of venom toxicity
by a single antibody can also be caused by an interruption of syn-
ergistic effects between toxins, if a key toxin (or key component) is
neutralized (Fig. 6). Toxin synergism is a well-known feature of
certain snake venoms (Laustsen, 2016). Each venom toxin may
exhibit low toxicity on its own, but when the individual toxins are
combined in a whole venom, they amplify the effect of each other
resulting in actions such as destabilization of phosphorylative
oxidation and increased tissue necrosis (Gasanov et al., 2014).
Consequently, understanding the toxicity and interplay between
individual toxins, as well as possible mechanisms of neutralization,
is key to rational design of future recombinant antivenoms.
Therefore, despite the great biochemical complexity of snake
venoms (Calvete, 2017) and other animal venoms, it is likely that, in
some cases, the neutralization of a few key toxins by antibodies
may result in a drastic reduction in overall venom-induced toxicity.3. Pharmacokinetics: distribution and elimination of
antibodies and antibody fragments
The efficacy of treatment for a therapeutic antibody is strongly
influenced by the speed and concentration at which it reaches the
site of action, as well as its residence time in the body and conse-
quent elimination. Upon injection, the pharmacological effect of the
antibody will vary according to its absorption, distribution, meta-
bolism, and excretion (ADME), pharmacokinetic (PK) processes that
depend largely on the structural and biophysical properties of the
molecule (Deng et al., 2012; Liu, 2017; Mould and Green, 2010). The
combination of these processes provides an antibody with a PK
profile, generally described by parameters such as volume of dis-
tribution (Vd), bioavailability (F), clearance (CL), maximum con-
centration in plasma (Cmax), and elimination half-life (t1/2), among
others, that are calculated after measuring the concentration in
plasma of the antibody over a period of time after its administration
(Fan and de Lannoy, 2014).
Generally, for antibodies and their fragments, there is a strong
relationship between the molecular mass of the molecule and its
distribution and elimination characteristics. The PK profiles of re-
combinant monoclonal IgG antibodies used for therapeutic pur-
poses (isotypes IgG1, IgG2, and IgG4) are characterized by limited
tissue distribution and long elimination half-lives (Fig. 7AeB),
displaying either linear or non-linear (dose-dependent) profiles
(Kamath, 2016; Keizer et al., 2010; Tabrizi et al., 2006). Distribution
of IgGs, which involves extravasation to the interstitial space and
elimination from tissue, occurs mainly by convection, as diffusion
Fig. 3. Modes of neutralization: Direct inhibition of non-enzymatic toxins. (A1) A
non-enzymatic toxin binds to its target (toxin binding region in blue), resulting in a
toxic effect. (A2) The antibody interferes with the functional site of the non-enzymatic
toxin, thereby preventing the toxin binding to the target. Direct inhibition of enzy-
matic toxins. (B1) An enzymatic toxin binds to the substrate resulting in enzymatic
degradation of the substrate. (B2) The antibody blocks (or distorts) the catalytic site of
the enzymatic toxin, thereby preventing substrate degradation. Inhibition by steric
hindrance. (C1) A toxin binds to its target (toxin binding region in blue), resulting in a
toxic effect. (C2) The antibody binds to a region near the site of interaction, thereby
preventing the toxin from binding to the target. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Modes of neutralization: Allosteric inhibition. (1) A toxin binds to its target,
resulting in a toxic effect. (2) The antibody binds to a distal site of the toxin, which
induces conformation changes, resulting in a less or non-functional toxin (allosteric
inhibition).
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drophilicity of the molecule (Lobo et al., 2004). Their large size also
impedes IgGs from being enzymatically metabolized by cyto-
chrome P450 (Mould and Green, 2010), and cleared by the kidneys
(glomerular filtration cut-off ~50 kDa) (Wang et al., 2008). Instead,
the main route for their elimination is via intracellular catabolismin the lysosomes, upon fluid-phase endocytosis (pinocytosis) or
receptor-mediated endocytosis, including binding to Fcg receptors
(FcgR) expressed by phagocytic cells (Keizer et al., 2010; Tabrizi
et al., 2006; Wang et al., 2008). However, a major fraction of the
internalized IgGs is rescued from rapid degradation through bind-
ing to the neonatal Fc receptor (FcRn) of cells in the mononuclear
phagocytic system (Fig. 7C), which transports the IgGs back to the
cell surface and facilitates their release into the extracellular fluid
(Brambell et al., 1964; Junghans, 1997); this is a saturable, pH-
dependent, recycling mechanism that confers a long half-life
(21e28 days) to human IgGs (Keizer et al., 2010; Raghavan et al.,
1995; Tabrizi et al., 2006; Wang et al., 2008). Of note, the affinity
of IgGs for FcRn is species dependent (Ober et al., 2001). Human
IgGs have a higher affinity for human FcRn than chimeric IgGs and
murine IgGs, which explains the shorter elimination half-lives of
the latter in humans (8e10 days and 1e3 days, respectively) (Deng
et al., 2012; Tabrizi et al., 2006).
In contrast to whole IgGs, the smaller sizes of antibody frag-
ments, such as Fabs, scFvs (monomers and dimers), VHHs, and
minibodies, account for a larger volume of distribution and faster
rate of tissue penetration (Harmsen and De Haard, 2007; Keizer
et al., 2010; Wu et al., 1999, 1996). Due to the lack of an Fc region
on these antibody fragments, they are unable to bind to the FcRn.
Also associated with their small size, the main route for their
clearance is via glomerular filtration by the kidneys (Lobo et al.,
2004; Tabrizi et al., 2006). Owing to these features, these anti-
body fragments possess considerably shorter half-lives (0.5e30 h)
(Tabrizi et al., 2006). F(ab')2 fragments, also devoid of Fc region,
possess a shorter half-life than IgGs, since recycling by the FcRn
rescue mechanism is not possible (Tabrizi et al., 2006). However,
their distribution profile resembles that of IgGs, and similarly,
elimination occurs mainly by non-renal mechanisms, as their size
exceeds the cut-off for renal filtration (Seifert and Boyer, 2001;
Tabrizi et al., 2006).
In addition to the structural and biophysical properties of the
antibody molecule, PK of IgGs and their fragments can be influ-
enced by specific patient conditions, such as age, gender, health
status (renal and hepatic function), or concomitant administration
of other drugs (Deng et al., 2012; Tabrizi et al., 2006). The interac-
tion between the antibody and the antigen may also affect PK
(Bauer et al., 1999; Meijer et al., 2002), as well as immune responses
Fig. 5. Modes of neutralization: Preventing dissociation. (1) A toxin complex is dissociated and the active toxins bind to their targets, resulting in a toxic effect. (2) Antibody
binding inhibits the dissociation of the toxin complex, thereby preventing the formation of active toxins.
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et al., 2007; Xu et al., 2008). Recently, several strategies to pro-
long the half-lives of antibodies and their fragments have been
explored, such as mutations in the Fc region to increase affinity
towards FcRn (Dall’Acqua et al., 2006; Finch et al., 2011; Monnet
et al., 2014), N-glycosylation (Stork et al., 2008), polysialylation
(Chen et al., 2012; Constantinou et al., 2008), PEGylation (Chapman
et al., 1999), modification of the isoelectric point (Boswell et al.,
2010; Kobayashi et al., 1999), and fusion or binding to proteins
having an extended half-life (e.g. albumin, immunoglobulin)
(Andersen et al., 2011; Evans et al., 2010; Hutt et al., 2012; Müller
et al., 2007; Sleep et al., 2013; Smith et al., 2001; Unverdorben
et al., 2012).
In agreement with the PK parameters displayed by whole re-
combinant IgGs and their fragments used as therapeutics, kinetic
studies of plasma-derived antivenoms have shown the same strong
relationship between the molecular mass of the molecules and
their PK profiles (Gutierrez et al., 2003). Antivenoms based on IgGs
have low volumes of distribution, long elimination half-lives, and a
high number of cycles through the interstitial spaces (Ho et al.,
1990; Ismail et al., 1998; Ismail and Abd-Elsalam, 1996).
Conversely, antivenoms based on Fab fragments, much smaller
than IgGs, have larger volumes of distribution, diffuse faster into
extravascular compartments, and have shorter elimination half-
lives (Ariaratnam et al., 2001, 1999; Brvar et al., 2017; Meyer
et al., 1997; Riviere et al., 1997; Vazquez et al., 2010a,b; Vazquez
et al., 2005). A negative consequence of the short elimination
half-life of Fab fragments is the higher incidence of recurrent peaks
in plasma venom levels, and therefore envenomation symptoms,
compared to IgG and F(ab')2 antivenoms. This is most probably due
to rapid clearance of Fab fragments from circulation that impedes
the neutralization of venom toxins released from the bite site in
later stages of the envenoming (Boyer et al., 2013; Gutierrez et al.,
2003; Seifert and Boyer, 2001). In accordance with their interme-
diate molecular mass, the PK profile of F(ab')2-based antivenoms
constitutes a middle point between that of IgGs and Fab fragments
(Boyer et al., 2013; Gutierrez et al., 2003; Ho et al., 1990; Isbister
et al., 2015; Kurtovic et al., 2016; Maung-Maung-Thwin et al.,
1988; Pepin-Covatta et al., 1996; Sevcik et al., 2004). However, in
general, due to the heterologous nature of antivenoms derived from
horse or sheep plasma, these antibodies are eliminated faster thanexpected for a homologous human antibody (Scherrmann, 1994).
The molecular mechanisms behind this observation are not fully
understood, but could be the result of impeded binding to FcRn
and/or development of anti-antibodies by the patient's immune
system (Tabrizi et al., 2006; Wang et al., 2008).
While information on animal plasma-derived antivenom PK is
somewhat available, only two studies have reported the PK profiles
of recombinant antibody fragments targeting animal toxins. Aubrey
et al. investigated the in vivo kinetics of a homodimeric diabody
(50 kDa) derived from the anti-AahI murine 9C2 antibody after
intraperitoneal injection into mice (Aubrey et al., 2003). The dia-
body displayed rapid diffusion, being detected in plasma only 5min
after its administration. Consequently, themaximum concentration
(Cmax) was reached shortly after (30e60min post-injection). High
concentrations (>50% of Cmax) were detected for at least 6 h, and
complete clearance of the diabody took approximately 24e32 h
(Aubrey et al., 2003). In the other study, Hmila et al. compared the
distribution and kinetics of two nanobodies (NbAahIF12 and
NbAahII10, 14 kDa each) and a bispecific nanobody construct
(NbF12-10, 29 kDa) to those of a F(ab')2-based (110 kDa) scorpion
antivenom after intravenous administration in mice and rats
(Hmila et al., 2012). In vivo monitoring of radiolabeled nanobodies
and F(ab')2 fragments revealed that the nanobody-based molecules
were cleared from blood faster than the F(ab')2 antivenom, most
likely due to the lower molecular mass of nanobodies. Additionally,
a major difference was observed in the organ accumulation of the
antitoxins. Monovalent nanobodies and the bispecific construct
accumulated mainly in the kidneys, whereas F(ab')2 fragments
were predominantly retained in the liver (Hmila et al., 2012).
PD has implications on PK profiles of antibodies, and this will
further have implications on efficacy, which highlights the impor-
tance of choosing the right antibody format for rational develop-
ment of novel antivenoms. Often, venoms consist of complex
mixtures containing both low and high molecular mass toxins,
acting locally and/or systemically (Fig. 7D). On one hand, anti-
venoms should ideally provide antitoxins able to rapidly reach
locally acting toxins and toxins that reach systemic extravascular
targets very fast, such as low molecular mass neurotoxins. On the
other hand, antivenoms should also provide antitoxins with
extended half-lives that remain in circulation for prolonged periods
of time (many hours to days). This will allow the antitoxins with
Fig. 6. Modes of neutralization: Preventing synergistic effects. (1) Synergism between toxin A (diamond) and B (circle) results in synergistically enhanced toxicity. (2) Antibody
binding to one of the toxins results in milder toxic (or no) effects due to disruption of synergism.
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in the circulatory system before these toxins reach their target site
(Gutierrez et al., 2003). Thus, an antivenom comprised of a mixture
of different antibody formats could be necessary to target all
medically relevant toxins present in complex venoms (Gutierrez
et al., 2003). Regarding the route of administration, notable dif-
ferences have been found when comparing intravenous adminis-
tration with intramuscular administration. Intravenous injections
directly deliver the antibodies to the bloodstream, avoiding the
absorption step and providing complete bioavailability (Liu, 2017).
Hence, it is considered the preferred route of administration for
antivenoms in a hospital setting. In contrast, intramuscularly
injected antivenoms have shown poor efficacy due to slow ab-
sorption and reduced bioavailability of the antibodies or theirfragments (Isbister et al., 2008a,b; Pepin-Covatta et al., 1996, 1995;
Vazquez et al., 2010a,b). Nevertheless, it could still be considered an
option, as antivenoms are occasionally required to be administered
in the field (Warrell, 1995). Although the PK of a specific antibody
format may be predicted based on the general distribution and
elimination characteristics typical for its molecular mass, more PK
studies are required to increase the current knowledge and guide
the development of recombinant antivenoms based on in-depth
understanding of the PK-PD relationship of each antibody format
on an individual case basis. Additionally, favorable PK-PD for a
given antibody format may very well depend on the toxicokinetics
of the target toxin(s).
Fig. 7. Antivenom pharmacokinetics. (A) Distribution profiles for different antibody formats, showing their volume of distribution (Vd). (B) Elimination mechanism for different
antibody formats, indicating their elimination half-life (t1/2). (C) IgG recycling by FcRn receptor. 1. IgGs and plasma proteins are internalized in vesicles by endocytosis. 2. IgGs bind to
FcRn receptors in the acidic endososome. 3. Non-FcRn bound proteins. 4. Proteins are degraded in the lysosome. 5. IgG-FcRn complexes are transported to the cell surface. 6. IgGs are
dissociated from the FcRn receptors at physiological pH. (D) The influence of the antibody format on pharmacokinetics in relation to toxicokinetics. The distribution of the larger IgG
antibody format is largely restricted to the intravascular compartment, where it is effective in neutralizing systemically acting toxins over a period of many days due to its long
elimination half-life. Smaller antibody fragments may both neutralize toxins in circulation, toxins present in or around the bite wound, and toxins that have reached systemic
targets in tissues, i.e. neuromuscular junctions, due to their larger volumes of distribution, which allow these smaller fragments to more effectively penetrate tissue compartments.
However, antibody fragments have a shorter elimination half-life. Systemically acting toxins are represented by scorpion stings and elapid snakebites, whereas viper snakebites
represent locally and systemically acting toxins, although all three types of bite/sting contain both locally and systemically acting toxins in their venom.
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formats
Adverse reactions to animal plasma-derived antivenoms are
relatively common, with 6e59% of patients experiencing early-
onset reactions, depending on the particular antivenom being
used. In rare cases, administration of animal plasma-derived anti-
venoms may result in severe life-threatening anaphylaxis
(Schaeffer et al., 2012; Stone et al., 2013). Further, 5e23% of treated
patients experience delayed-onset serum sickness (typically
observed 1e2 weeks after exposure), with symptoms such as high
fever, rash, urticaria, and arthralgia (LoVecchio et al., 2003). The
propensity of an animal-derived antivenom to generate early and
late adverse reactions depends on the microbiological and physi-
cochemical quality of the product, its format (i.e. Fab, F(ab’)2, or
IgG), and the total amount of protein injected in a treatment (Leonet al., 2013). A relatively low rate of early adverse reactions (5e7%)
has been reported for a highly purified Fab antivenom in use in the
USA, which includes an affinity chromatography purification step in
its manufacture (Cannon et al., 2008; Farrar et al., 2012). In com-
parison, F(ab’)2 and IgG antivenoms of good physicochemical
quality induce early adverse reactions in 13e26% of treated patients
(see review by (Leon et al., 2013)). In these cases, the majority of
such reactions are mild, including mostly cutaneous manifesta-
tions. In contrast, other antivenoms of poor physicochemical
quality, or containing pyrogens, are known to induce a rate of
adverse reactions as high as 80%, with some of these reactions
being severe (Leon et al., 2013). Most early adverse reactions to
antivenoms are de novo reactions, i.e. occurring in people who have
not been previously sensitized with antivenoms and are, therefore,
non-IgE-mediated. In fact, only a small proportion of early adverse
reactions are IgE-mediated (Leon et al., 2013).
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adverse reactions, a type III hypersensitivity phenomenon associ-
ated with serum sickness (Leon et al., 2013). This occurs approx-
imately 1e2 weeks after antivenom infusion as a consequence of
the generation of human antibodies against animal IgGs, and the
consequent formation of antigen-antibody complexes, which exert
effects in the microvasculature and the joints, causing arthralgia,
fever, and urticaria (Gutierrez et al., 2017a). The incidence of
serum sickness after antivenom administration has not been
analyzed in depth, although it seems to depend on the total load of
foreign protein administered (LoVecchio et al., 2003) and on the
format of the antivenom preparation. In particular, Fab antivenoms
have been shown to induce a much lower incidence of serum
sickness than IgG and F(ab’)2 antivenoms (Lavonas et al., 2013;
Leon et al., 2013). A detailed account of the studies reporting in-
cidences of adverse reactions to animal-derived antivenoms can
be found in (see reviews by Descotes (2009) and Hansel et al.
(2010)).
There are no antivenoms in clinical use that are comprised of
monoclonal antibodies or of any type of recombinant product. In-
formation on safety of other biotherapeutics based on monoclonal
antibodies may instead be utilized to shine light on the potential
challenges that recombinant antivenoms may face, when they
become available in the future. Murine monoclonal antibodies have
been shown to induce early and late adverse reactions in humans
(see reviews by Descotes (2009) and Hansel et al. (2010)), owing to
their heterologous nature, including anaphylactic reactions in a few
cases and serum sickness. As a result, biotherapeutics based on
murine antibodies are no longer put into development and enter
clinical trials. The propensity to generate adverse reactions has,
however, been greatly reduced by the generation of chimeric, hu-
manized, and fully human monoclonal antibodies, although it is
still possible to generate anti-idiotype antibodies with such prod-
ucts (Hansel et al., 2010). For example, a humanized monoclonal
antibody against an integrin has been reported to induce early
adverse reactions (urticaria) in 4% of patients (Ransohoff, 2007).
Despite these observations, the introduction of humanized or fully
human monoclonal antibodies in the development of new anti-
venoms is likely to greatly reduce the incidence of early and late
adverse reactions, currently observed for animal plasma-derived
antivenoms, owing to the greater compatibility of these products
with the human immune system (Laustsen, n.d.). Likewise, the fact
that antivenoms are usually used only once in a single individual
further reduces the likelihood of development of adverse reactions.
From a theoretical viewpoint, it is also probable that recombinant
antivenom antibodies of low molecular mass formats, such as Fab,
scFv, VHH, diabodies, bivalent constructs, and other binding protein
formats, will be less prone to induce adverse reactions than whole
IgG preparations. However, this should be carefully balanced with
other aspects such as PK profile and the possible role of the Fc part
of the immunoglobulin in its biological action. Finally, optimization
of antibody glycosylation to better resemble human patterns may
lead to recombinant antivenom formats with even better compat-
ibility with the human immune system. All these issues demand
renewed research vis-a-vis the current upsurge in the development
of recombinant antivenoms.5. Formulation
Owing to the proteinaceous nature of antibodies, antivenoms
face many of the generic issues commonly related to high-protein-
concentration solutions. Antivenom antibodies are especially
susceptible to degradation when exposed to heat, freezing, light,
pH extremes, shear-stress, agitation, as well as to some metals andorganic solvents (Lowe et al., 2011). Particularly heat stability is
important for long term storage in tropical regions, where most
envenomings occur (Gutierrez et al., 2006; Warrell, 2007). Liquid
antivenom should generally be stored at 2e8 C, but this
requirement is not always possible to fulfil in rural areas where
the cold-chain is often interrupted or non-existent. When stored
at room temperature, formation of turbidity over time is observed
in liquid formulations, indicating physical instability and decrease
in biological activity (Segura et al., 2009). To overcome this issue,
many antivenom manufacturers lyophilize their antivenoms,
although this adds to the cost of manufacture (Segura et al., 2009).
As an example, two studies on EchiTAb-Plus-ICP antivenom used
to treat snakebite victims in rural sub-Saharan Africa attempted to
determine the optimal state for antivenom stability. These studies
indicated that freeze-drying offered the best thermal stability of
the antivenom compared to liquid formulation without stabilizer
and liquid formulation stabilized with sorbitol (Herrera et al., 2017,
2014). Most of the current research efforts are, however, focused
on finding a stable liquid formulation that can be stored at room
temperature. As an example, Solano et al. (2012) described that an
acetate buffered (pH 4.0) formulation stabilized antivenoms for at
least six months at room temperature without the presence of a
protective carbohydrate excipient (Solano et al., 2012).
Some antivenom formulation additives have been reported to
have varying levels of effects depending on the combination of
additive molecules used and on whether the additives are added
to liquid or lyophilized formulations. In a study that compared the
stabilizing effects of sorbitol, sucrose, and mannitol in lyophilized
antivenom, Herrera et al. (2014) showed that antivenoms lyophi-
lized with mannitol lost efficacy against the lethal effects of
B. asper venom (Herrera et al., 2014). Furthermore, it was shown
that a 5% (w:v) sucrose formulation exhibited the best stability,
indicating that sucrose could perform better as a stabilizer than
mannitol and sorbitol in lyophilized antivenoms. Of the additives
used in antivenom formulation, the most commonly used are
phenol, cresol, and sodium chloride (see Table 5). These additives
stabilize and preserve the antivenom by preventing aggregation of
IgGs and/or antibody fragments, by providing an isotonic solution,
and by having antifungal and bacteriostatic effects (Rodrigues-
Silva et al., 1999; Segura et al., 2009). Preventing aggregation for
therapeutic antibodies is crucial, as aggregation may significantly
contribute to their immunogenicity (Rosenberg, 2006; van Beers
et al., 2010).
Other less conventional formulations explored at the experi-
mental level focus on enhancing the neutralization ability through
conjugation of protein nanoparticles and/or facilitating the
administration through encapsulation. Renu et al. (2014) used soy
protein nanoparticles conjugated to F(ab’)2 fragments to optimize
the neutralizing effects of Bungarus caeruleus antivenom (Renu
et al., 2014). They achieved to produce the smallest size of self-
stabilized soy protein nanoparticle reported within antivenom
research, which displayed improved neutralization capacity against
toxins from B. caeruleus venom at a much lower concentration
compared to the non-conjugated antivenom. The conjugated anti-
venom particles also showed enhanced thermal stability (Renu
et al., 2014).
Certain formulations could allow for alternative routes of anti-
venom administration. These formulations are being explored to
allow non-physicians to aid snakebite victims before the victim
reaches a clinic or hospital. Currently, all antivenoms are adminis-
tered by intravenous bolus injection and/or intravenous infusion
(Ahmed et al., 2008). Compared to other common routes of
administration (e.g. intramuscular route), intravenous injection
offers the fastest route to maximum concentration of antivenom in
Table 5
Different formulations used for antivenoms.
Trade name Format Formulation Additive molecule Benefit of additive References
Studies performed on antivenom formulation
Ovine Fab Liquid Acetate buffer Buffer and
stabilizationa
(Al-Abdulla et al., 2003)
Equine F(ab’)2 Liquid Sorbitol, phenol Buffer and
preservationb
(Solano et al., 2012)
Equine Lyophilized Sorbitol/Mannitol/
Sucrose
Stabilization (Herrera et al., 2014)
Equine F(ab’)2 Liquid Alginate
encapsulation
Oral delivery (Bhattacharya et al., 2014)
Equine IgG Liquid Phenol, sorbitol,
sodium chloride
Preservation,
protection against heat
denaturation
(Segura et al., 2009)
Equine Liquid Phenol/Sorbitol Preservation,
protection against heat
denaturation
(Rodrigues-Silva et al., 1999)
Equine IgG/Equine
F(ab’)2
Liquid Sorbitol Protection against heat
denaturation
(Rodrigues-Silva et al., 1997)
Equine F(ab’)2 Liquid Conjugated soy
protein NP's
Improvement of venom
neutralization
efficiency
(Renu et al., 2014)
mAb Liquid PBS e (Bugli et al., 2008)
EchiTAb + ICP Equine IgG Liquid/
Lyophilized
Sorbitol/sucrose Stabilization,
protection against heat
denaturation
(Herrera et al., 2017)
Snake antivenoms currently on market with disclosed formulation
ViperaTAb Equine F(ab’)2 Liquid Sodium acetate
buffer
Buffer (“Product information. ViperaTAb.,” n.d.)
Snake Antivenin
(Polyvalent) I.P.
Equine Liquid Phenol Preservation (“Product information. Snake Antivenin
(Polyvalent) I.P.,” n.d.)
Snake Venom
Antiserum I.P.
Equine Liquid Cresol Preservation (“Product information. Snake Venom Antiserum
I.P.,” n.d.)
Anavip Equine F(ab’)2 Lyophilized Sodium chloride,
sucrose, glycine
Stabilization (“Product information. Anavip.,” n.d.)
CroFab Ovine Fab Lyophilized PBS Buffer ((“Crofab Crotalidae Polyvalent Immune Fab
Ovine,” n.d.))
Suero Antiofidico
polivalente
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Suero Antiofidico polivalente. Centro de
Biotechnologia Facultad de Farmacia.,” n.d.)
Black Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Black Snake
Antivenom.,” n.d.)
Brown Snake
Antivenom
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Brown Snake
Antivenom.,” n.d.)
Death Adder
Antivenom
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Death Adder
Antivenom.,” n.d.)
Polyvalent Snake
Antivenom
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Polyvalent Snake
Antivenom.,” n.d.)
Sea Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Sea Snake Antivenom - Current Consumer
Medicine information.,” n.d.)
Taipan Antivenom Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Taipan Antivenom - Curent Consumer
Medicine information Nov 2017.,” n.d.)
Tiger Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Tiger Snake Antivenom - Current Consumer
Medicine Information Oct 2016.,” n.d.)
Soro Antielapídico
(bivalente)
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation ((“Product information. Soro Antielapidico
bivalente.,” n.d.))
Soro Antibotropico
(pentavalente) e
Antilaquetico
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation ((“Product information. Soro Antibotropico
pentavalente e antilaquetico.,” n.d.))
Soro Anticrotalico Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Soro Anticrotalico.,” n.d.)
Soro Antibotropico
(pentavalente) e
Anticrotalico
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation ((“Product information. Soro antibotropico
pentavalente e anticrotalico.,” n.d.))
Soro Antibotropico
(pentavalente)
Equine F(ab’)2 Liquid Phenol Preservation (“Product information. Soro Antibotropico
(pentavalente).,” n.d.)
Suero Antibotropico
polivalente
Equine IgG Liquid Phenol, thimerosal Preservation (Biologicos et al., n.d.)
Suero Anticrotalico
monovalente
Equine IgG Liquid Phenol, thimerosal Preservation (Biologicos et al., n.d.)
Suero Antilachesico
monovalente
Equine IgG Liquid Phenol, thimerosal Preservation (Biologicos et al., n.d.)
Suero Antiloxoscelico
monovalente
Equine F(ab’)2 Liquid Phenol, thimerosal Preservation (Biologicos et al., n.d.)
EchiTAbG antivenom Ovine IgG Liquid PBS Buffer (Casewell et al., 2010)
EchiTAb-Plus-ICP Equine IgG Liquid Phenol, sodium
chloride
Preservation, (Segura et al., 2010)
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Table 5 (continued )
Trade name Format Formulation Additive molecule Benefit of additive References
Banded Krait Antivenin Equine IgG Lyophilized Glycine, phenol,
sodium chloride
Preservation, stabilizer (“Product information. Banded Krait
Antivenin.,” n.d.)
Viper Venom Antitoxin Equine IgG Liquid Phenol, sodium
chloride
Preservation (“Product information. Viper Venom
Antitoxin.,” n.d.)
Snake Venom
Antiserum
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Snake Venom Antiserum -
Lyophilized.,” n.d.)
Snake Venom
Antiserum I.P
Equine F(ab’)2 Liquid Cresol, glycine,
sodium chloride
Preservation, stabilizer (Premium Serums. Snake Venom Antiserum I.P.,
n.d.)
Snake Venom
Antiserum (Central
Africa)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Snake Venom Antiserum
(Central Africa).,” n.d.)
Snake Venom
Antiserum (Pan
Africa)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Snake Venom Antiserum
(Pan Africa).,” n.d.)
Snake Venom
Antiserum (African
e Ten)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Snake Venom Antiserum
(African - Ten).,” n.d.)
Snake Venom
Antiserum (North
Africa)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Snake Venom Antiserum
(North Africa).,” n.d.)
Scorpion antivenoms currently on market with disclosed information
Scorpion Venom
Antiserum (India)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Scorpion Venom Antiserum
(India).,” n.d.)
Scorpion Venom
Antiserum (North
Africa)
Equine F(ab’)2 Lyophilized Cresol, glycine,
sodium chloride
Preservation, stabilizer (“Premium Serums. Scorpion Venom Antiserum
(North Africa).,” n.d.)
Suero antiescorpionico Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation,
stabilization
(“Suero antiescorpionico. Centro de
Biotechnologia Facultad de Farmacia.,” n.d.)
Alacramyn Equine Fab Lyophilized Cresol Preservation (“Instructions for use. Alacramyn®.,” n.d.)
Soro antiarachnidico Equine F(ab’)2 Liquid Phenol Preservation (“Package leaflet: Soro antiarachnidico -
Butantan.,” n.d.)
Soro antiescorpio^nico Equine F(ab’)2 Liquid Phenol Preservation (“Package leaflet: Soro antiescorpionico -
Butantan.,” n.d.)
Polyvalent Scorpion
Antivenom
Equine F(ab’)2 Liquid Cresol, PBS Preservation (“Polyvalent Scorpion Antivenom j National
Antivenom and Vaccine Production Center.,”
n.d.)
Scorpifav Equine F(ab’)2 Liquid Sodium chloride,
polysorbate 80
Preservation (“MAVIN Poison Centre Munich - Scorpifav.,”
n.d.)
Scorpion Venom
Antiserum
Equine IgG Lyophilized Ortho-cresol Preservation (“Scorpion Anti Serum j VINS BioProducts
Limited,” n.d.)
Soro Antiescorpio^nico
(FUNED)
Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Product information. Soro Antiescorpio^nico
(FUNED).,” n.d.)
Anti-scorpion Venom
Serum
Equine IgG Lyophilized Phenol Preservation (“Antitoxins & Sera: Antiscorpion venom
serum,” n.d.)
Spider antivenoms currently on market with disclosed information
Funnel Web Spider
Antivenom
Leporid IgG Lyophilized Glycine, sodium
chloride, sodium
phosphate e
dibasic, sodium
phosphate -
monobasic
Preservation,
stabilization
(“Funnel Web Spider Antivenom - Current
Cunsumer Medicine Information Jan 2017.,”
n.d.)
Red Back Spider
Antivenom
Equine IgG Liquid Phenol, sodium
chloride
Preservation (“Red Back Spider Antivenom - Current
Consumer Medicine Information Febr, 2017.,”
n.d.)
Aracmyn PLUS Equine F(ab’)2 Lyophilized Cresol Preservation (“Aracmyn Plus - Bioclon j PR Vademecum
Mexico,” n.d.)
Reclusmyn Equine F(ab’)2 Lyophilized Cresol Preservation (“Our Products - Reclusmyn.,” n.d.)
Soro antiarachnidico Equine F(ab’)2 Liquid Phenol Preservation (“Package leaflet: Soro antiarachnidico -
Butantan.,” n.d.)
Suero antiloxoscelico
monovalente
Equine IgG Liquid Thimerosal, phenol Preservation (“Detalle del Producto. Suero antiloxoscelico
monovalente.,” n.d.)
Soro Antilatrodectico Equine F(ab’)2 Liquid Phenol, sodium
chloride
Preservation (“Instituto Vital Brazil - Soro Antilatrodectico.,”
n.d.)
Antivenin (Latrodectus
mactans)
Equine IgG Lyophilized Thimerosal Preservation (“Antivenin (Latrodectus mactans).,” n.d.)
a Stabilization implies benefits that prevent aggregation of IgGs and/or IgG fragments.
b Preservation implies antifungal and bacteriostatic benefits.
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infusion of foreign antivenom proteins may result in adverse re-
actions often experienced by patients upon antivenom adminis-
tration (Leon et al., 2013). An approach to minimize the adverse
effects of antivenom, that has only been explored once experi-
mentally, involves oral administration of alginate encapsulated
antivenom (Bhattacharya et al., 2014). However, even if antibodies
can be properly formulated for oral administration, oral delivery of
an emergency medicine will come at a cost to bioavailability and
the delayed arrival of antibodies may not be optimal for efficient
toxin neutralization. Thus, even if such formulations may one day
be useful in the field, they will have to be supplemented with
intravenously administered antivenom once the snakebite victim
reaches a clinic or hospital.
In conclusion, it is observed that the majority of antivenoms
currently on the market are formulated with one or more of the
excipients phenol, cresol, sodium chloride, glycine in some prod-
ucts and, in the case of freeze-dried antivenoms, sucrose. Most of
the available data on antivenom formulation is based on plasma-
derived equine or ovine polyclonal F(ab’)2s, possibly due to the
early stage of development for recombinant antivenoms based on
monoclonal antibodies. It seems likely that antivenom researchwill
increasingly focus onmore modern approaches involving the use of
recombinant human antibodies (Laustsen, n. d.; Laustsen et al.,
2017). With such a shift, more research is needed in order to
develop and optimize formulations of mixtures of monoclonal
antibodies. These future efforts will fortunately not start from
scratch. In other fields, (mixtures of) humanmonoclonal antibodies
have been extensively used, and existing formulation solutions
from these fields are likely to also be applicable for recombinant
antivenoms (Heijtink et al., 1999; Robak et al., 2012).6. Expression of different antibody formats
To enable large-scale production of novel antivenoms consisting
of recombinant antibodies or antibody fragments, a suitable
expression system is essential. To the best of our knowledge, so far,
no monoclonal antibody nor antibody fragment targeting an ani-
mal toxin has been produced in larger scale. Several different
research efforts have, however, employed different expression
hosts, which will be reviewed in the following for their suitability
for Research and Development (R&D) purposes and scale up.6.1. Key differences between eukaryotes and prokaryotes in
antibody expression
Antibodies and antibody fragments can be expressed in either
prokaryotic or eukaryotic cells, depending on the structure of the
protein product and the application of the desired antibody frag-
ment. These cell types are inherently different and thus offer
different advantages and disadvantages in relation to antibody
expression (Berlec and Strukelj, 2013).
Advantages of prokaryotic expression of antibodies include low
cost of media and ease of handling. For these reasons, E. coli has
been a much-used organism for expression of several different
antibody formats within antivenom research. However, the
inability of prokaryotes to glycosylate antibodies limits the range of
antibody formats that can be expressed with these systems.
Therefore, E. coli has mainly been used to produce diabodies, scFvs,
Fabs, and VHHs (see Table 6). Furthermore, the tendency to form
incorrectly folded proteins and insoluble aggregates in the reducing
environment of the bacterial cytoplasm decreases expression
yields. Other prokaryotes that are more promising than E. coli for
production of biotherapeutics could be strains of the genus Bacillus,which have a long track record of successful use for expression of
both heterologous and homologous proteins (Lakowitz et al., 2017).
These have, however, not yet been employed within the field of
antivenom.
In contrast to prokaryotic cells, mammalian cells are capable of
performing more advanced post-translational modifications, such
as glycosylation, and possess more complex cellular machinery for
folding and secretion (Chadd and Chamow, 2001; Frenzel et al.,
2013). Mammalian cells are capable of yielding more diverse anti-
body formats with lower immunogenicity (Chadd and Chamow,
2001; Frenzel et al., 2013) and are the primary production system
for full IgG molecules (Walsh, 2014). Also, mammalian cells typi-
cally deliver close to 100% fully functional proteins, in contrast to
prokaryotic expression systems, where the yield of active protein
may be significantly lower than the overall protein yield. However,
drawbacks for mammalian cells include high cost of media and
consumables, difficulty in handling, and (arguably) slow growth
rate. Productivity has, however, been increased significantly in
recent decades by optimization of protein expression levels for
many of themammalian cell lines employed in industrial processes,
which compensates for the slower growth of mammalian cells
compared to prokaryotes. Previously, pathogenic contaminations of
cell cultures also posed a threat, but modern protocols for avoiding
such contaminations limit this issue (Frenzel et al., 2013).6.2. scFvs are typically expressed in E. coli
The use of E. coli as an expression host appears to be the most
commonly used system within antivenom research, not only for
scFvs, but also for other antibody fragments (see Table 6). In 1999,
Mousli et al. expressed an scFv in E. coli. capable of neutralizing the
AahII toxin of the desert scorpion, Androctonus australis hector
(Mousli et al., 1999). More recently, scFv expression in E. coli cells
has been optimized, leading to improved expression yields. As an
example, signal peptides that localize antibody fragments to the
oxidative environment of the periplasm are often added to the
expression plasmid (Amaro et al., 2011; Juarez-Gonzalez et al.,
2005; Juste et al., 2007; Pucca et al., 2012; Roncolato et al., 2013).
The oxidative environment allows for the formation of disulphide
bond, which is normally unattainable in the reducing cytoplasmic
environment of E. coli, wherein expression tends to lead to non-
functional aggregates. Research groups outside of the field of an-
tivenom have attempted different strategies as alternatives to
localizing antibodies to the periplasm to achieve a higher degree of
correct folding. These strategies include: (i) denaturation and
refolding of cytoplasmic, aggregated antibodies, (ii) increased
expression of cytoplasmic chaperones in addition to altering the
cytoplasmic environment by creating mutations in reductases, (iii)
creating cysteine-free antibodies, and (iv) cytoplasmic oxidase
expression (Frenzel et al., 2013; Gaciarz et al., 2016; Veggiani and
De Marco, 2011). These methods have been employed with vary-
ing degrees of success. Denaturation and refolding does often not
prove efficient, whereas increasing the expression of chaperones
and cytoplasmic oxidases have successfully increased yields for Fab
and VHH fragments, respectively (Frenzel et al., 2013; Gaciarz et al.,
2016).
Engineering of expression vectors, such as optimization of co-
dons, promotor, Shine-Dalgarno sequence, leader sequence, and
transcript stability, can further improve scFv expression in E. coli
(Frenzel et al., 2013). Furthermore, cultivation of E. coli in bio-
reactors instead of shake flasks has in some cases significantly
increased scFv yields. As an example of shake flask cultivation,
Kipriyanov et al. obtained a yield of 16.5mg/L for an scFv against
the T cell surface antigen CD3 by expression in E. coli cultivated in
Table 6
Expression of antibody formats targeting spider, scorpion, and snake toxins.
Format Origin Expression system Yield Note Reference
Diabody mixture Human E. coli (strain: TG1) 1.5mg/L & 2.4mg/L (Rodríguez-Rodríguez et al.,
2012)
Murine E. coli (strain: HB2151) (di Tommaso et al., 2012)
0.5 e 0-8mg/L (Aubrey et al., 2003)
Nb/VHH Camelid E. coli (strain: WK6) (Hmila et al., 2012)
Camelid (dromedary) E. coli (strain: WK6) 3.75mg/L (Hmila et al., 2010)
3mg/L (Hmila et al., 2008)
1:15000 (Abderrazek et al., 2009)
Camelid (camel) E. coli (strain: BL21 (DE3)) Humanized (Chavanayarn et al., 2012)
Camelid (llama) E. coli (strain: BL21 (DE3)) Pentamerised (Stewart et al., 2007)
E. coli (strain: HB2151) 12-18mg/L. Titre: 3.0 105 VhH2-Fc (Richard et al., 2013)
scFv Human E. coli (strains: TG1 and HB2151
E. coli non-suppressor lineages
[K12, ara, D(lac-pro), thi/F'proA
þ Bþ, laclqZDM15])
1.24 1016 (Pessenda et al., 2016)
E. coli (strain: HB2151) 3.27 108 CFU/mL (Tamarozzi et al., 2006)
0.4e0.6mg/L (Roncolato et al., 2013;
Tamarozzi et al., 2006)
(Pucca et al., 2014, 2012)
1.3 107 CFU/mL (Oliveira et al., 2009)
E. coli (strain: TG1) (Ria~no-Umbarila et al.,
2016)
1.5mg/L (Ria~no-Umbarila et al.,
2013)
1.0e2.4mg/L (Ria~no-Umbarila et al.,
2011)
0.7mg/L (Ria~no-Umbarila et al.,
2005)
(Rodríguez-Rodríguez et al.,
2016)
(Cardoso et al., 2000)
1.0mg/L (Amaro et al., 2011)
E. coli (strains: BL21 (DE3) &
HB2151)
(Danpaiboon et al., 2014;
Kulkeaw et al., 2009)
Murine E. coli (strain: C43 (DE3)) 280 mg/L (Castro et al., 2014)
E. coli (strain: TG1) 0.3e1.0mg/L (Juarez-Gonzalez et al.,
2005)
(Devaux et al., 2001b)
E. coli (strain: BL21 (DE3)) 1mg/mL after purification (Meng et al., 1995)
E. coli (strain: HB2151) (Mousli et al., 1999)
E. coli (strain: HB2151 [K12, ara,
D(lac-pro), thi/F0 proAþ
Bþ, laclq lacZDM15])
0.1mg/L Tandem scFv (Juste et al., 2007)
E. coli (strain: W3110) (Merienne et al., 1997)
Fab Murine E. coli (strains: XL1-Blue,
BL21(DE3)pLysS, and Rosetta
2(DE3)pLysS)
0.5e1.5mg/L (Bugli et al., 2008)
E. coli (strain: TOPP2) 1mg/L (Selisko et al., 2004)
E. coli (strain: HB2151) 0.02mg/L Recombinant (Aubrey et al., 2004)
IgG Equine, murine Hybridoma cells (in vivo
hybridoma cultivation/ascite)
(Alvarenga et al., 2003)
Human Hybridoma cells (in vitro
hybridoma cultivation)
1:4000 (Morine et al., 2008)
Murine Hybridoma cells (in vivo
hybridoma cultivation/ascite)
(Perez et al., 1984)
(Clot-Faybesse et al., 1999)
(Frauches et al., 2013)
(Li et al., 1993)
(Alvarenga et al., 2005)
Hybridoma cells (in vitro
hybridoma cultivation)
(Jia et al., 2000)
Hybridoma cells (Charpentier et al., 1990)
IgG1 Murine Hybdridoma cells (in vivo
hybridoma cultivation/ascite)
Licea et al. describe a Fab
fragment derived from the
IgG originally produced by
Zamudio et al.
(Licea et al., 1996; Zamudio
et al., 1992)
(Masathien et al., 1994, p. 3,
p. 3)
Titres: 1:105e1:106 (Lomonte et al., 1992;
Lomonte and Kahan, 1988)
10.8mg/mL (Iddon et al., 1988)
Hybridoma cells (in vitro
hybridoma cultivation)
(Schneider et al., 2014)
1/1024 for whole venom (Fernandes et al., 2010)
The greatest dilutions were
of the order 104-105
(Tanjoni et al., 2003a,
2003b)
(Bahraoui et al., 1988)
(continued on next page)
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Table 6 (continued )
Format Origin Expression system Yield Note Reference
IgG2 Murine Hybridoma cells (in vitro
hybridoma cultivation)
1/1024 for whole venom (Fernandes et al., 2010)
IgG2a Murine Hybridoma cells (in vivo
hybridoma cultivation/ascite)
(Stiles et al., 1994)
(Tremeau et al., 1986)
IgG2b Murine Hybridoma cells (in vivo
hybridoma cultivation/ascite)
(Stiles et al., 1994)
(Masathien et al., 1994, p. 3,
p. 3)
IgM Murine Hybridoma cells (in vitro
hybridoma cultivation)
1/1024 for whole venom (Fernandes et al., 2010)
Hybdridoma cells (in vivo
hybridoma cultivation/ascite)
(Masathien et al., 1994, p. 3,
p. 3)
Ig Murine Hybridoma cells (in vivo
hybridoma cultivation/ascite)
2 mg/mouse (Boulain et al., 1982)
Hybridoma cells (in vitro
hybridoma cultivation)
(Dias-Lopes et al., 2014)
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parison, Sletta et al. obtained a much higher yield of 1.2 g/L for the
same scFv after optimization by using bioreactor production
(Kipriyanov et al., 1997; Sletta et al., 2004). Nevertheless, bioreactor
production may not generally be superior to shake flask produc-
tion, and examples of high scFv expression yields when using shake
flasks also exist. For instance, Gaciarz and colleagues were able to
obtain yields of 240mg/L for an scFv by shake flask cultivation of
E. coli (Gaciarz et al., 2016).6.3. Fabs are typically expressed in E. coli
Within antivenom research, Fabs have primarily been produced
in E. coli strains (Table 6). Many of these strains have been engi-
neered to circumvent problems inherent to expression of
mammalian proteins in prokaryotic cells. As an example, E. coli
strains have been modified to compensate for the limited avail-
ability of tRNAs corresponding to codons infrequently used in
prokaryotes, but frequently used in eukaryotes. Bugli et al. tested
such an E. coli strain and found that increasing the intracellular
availability of tRNAs with anticodons for AGG, AGA, AUA, CUA, CCC,
and GGA also increased yields of their Fab directed against alpha-
latrotoxin from the venom of L. tredecimguttatus (Mediterranean
black widow) from 0.5mg/L to 1.5mg/L (Bugli et al., 2008).
Optimization of growth media and additives, timing and dura-
tion of induction, concentration of reactants used for induction, and
other parameters may dramatically increase antibody expression
yields (Kipriyanov et al., 1997; Selisko et al., 2004; Ukkonen et al.,
2013). Although still in the lower range of yields, this is demon-
strated by a study of a Fab capable of neutralizing whole venom
antigens of the C. noxius scorpion, in which Fab yields were
increased by a factor of 20 (from 0.05mg/L to 1mg/L) through
optimization of addition of sucrose to the medium, temperature
and timing of induction, and concentration of the induction agent
(Selisko et al., 2004). In the same study, Selisko and colleagues also
found that lowering the temperature of induction in their case had
a profound positive impact on the yield of biologically active pro-
tein, as this reduced the number of insoluble, cytoplasmic aggre-
gates (Selisko et al., 2004). Conversely, however, Aubrey et al. found
that inducing expression at low temperatures resulted in extensive
cytoplasmic aggregation and low Fab yields (Aubrey et al., 2004).
This demonstrates that the temperature of induction is of para-
mount importance for correct folding, but that the optimal tem-
perature may be different from case to case.
Similar to scFvs, Fabs are often localized to the periplasm to
promote disulphide bond formation and ameliorate aggregations
(Aubrey et al., 2004; Bugli et al., 2008; Selisko et al., 2004). An
alternative solution to periplasmic expression from outside thefield of antivenom is introduction of enzymes (e.g. protein disul-
phide isomerase) facilitating disulphide bond formation in the
cytoplasm, as used by Gaciarz and colleagues for Fab expression
(Gaciarz et al., 2016). Thus, it is important to consider in which
cellular space the Fab fragment should be localized to achieve the
highest possible yield.
6.4. Diabodies and VHHs are expressed in E. coli
E. coli is also a widely employed expression host for diabodies
(Aubrey et al., 2003; di Tommaso et al., 2012; Rodríguez-Rodríguez
et al., 2012) and VHHs (Abderrazek et al., 2009; Chavanayarn et al.,
2012; Hmila et al., 2012, 2010, 2008; Richard et al., 2013; Stewart
et al., 2007), which similarly to scFvs and Fabs are often targeted
to the periplasm to promote disulphide bond formation and proper
folding (Abderrazek et al., 2009; Aubrey et al., 2003; di Tommaso
et al., 2012; Hmila et al., 2010, 2008; Richard et al., 2013). Dia-
bodies and VHHs have been developed against toxins from snakes
and, to a slightly greater extent, scorpions, whereas to the best of
our knowledge, no diabodies nor VHHs have been directed towards
spider toxins. Specifically, three VHH studies all focused on two
different N. kaouthia (cobra) toxins (Chavanayarn et al., 2012;
Richard et al., 2013; Stewart et al., 2007), while one study describes
diabodies directed against C. noxius (scorpion) venom antigens
(Rodríguez-Rodríguez et al., 2012), and six studies (two diabody
studies and four VHH studies) were all concerned with antibodies
directed against AahI and AahII toxins from A. australis hector
(scorpion) venom (Abderrazek et al., 2009; Aubrey et al., 2003; di
Tommaso et al., 2012; Hmila et al., 2012, 2010, 2008).
6.5. IgGs are expressed in mammalian hybridoma cell lines within
antivenom R&D
Although aglycosylated IgGs have been produced in E. coli cells
(Frenzel et al., 2013), a muchmore commonly employed expression
organism for IgGs for research use is hybridoma cells. Hybridomas
are generated by fusion of antibody-producing, mammalian, B
lymphocytes (typically murine cells) from immunized animals and
an immortalized cell line of choice. Hybridomas thus present ad-
vantages and disadvantages, making them suited for R&D pur-
poses, but less suited for large-scale production. As their most
relevant feature, they are immortalized and capable of antibody
production. Antibody expression in hybridoma cells has been
extensively used within the field of antivenoms, as illustrated by
Table 6, especially for the IgG format, partially due to the difficulty
of expressing functional versions of the IgG format in prokaryotes.
In 2008, Morine and colleagues produced two IgGs capable of
neutralizing both the haemorrhagic and proteolytic activities of the
A.H. Laustsen et al. / Toxicon 146 (2018) 151e175 167snake venom metalloproteinase Hr1a (Morine et al., 2008). These
IgGs were produced by hybridomas cultivated in vitro and har-
vested from the culture supernatant (Morine et al., 2008). Others
have followed similar procedures for expression of toxin-
neutralizing IgGs (Bahraoui et al., 1988; Jia et al., 2000). Another
approach entails in vivo production and harvest of IgGs from ascitic
fluids (Alvarenga et al., 2005, 2003; Boulain et al., 1982; Clot-
Faybesse et al., 1999; Frauches et al., 2013; Licea et al., 1996; Li
et al., 1993; Lomonte et al., 1992; Lomonte and Kahan, 1988;
Masathien et al., 1994; Perez et al., 1984; Stiles et al., 1994; Tremeau
et al., 1986; Zamudio et al., 1992). Several reasons for favouring this
approach exist for research purposes. Some hybridoma cell lines do
not growwell in vitro, and purification of IgAs, IgMs, and IgG3s from
in vitro cultures may result in denaturation and consequent loss of
activity (Ward et al., 1999). Thus, if high antibody concentrations
and activity levels are needed for preliminary studies and a small
degree of impurity is permissible, growing hybridomas inside the
peritoneal cavity of mice may be preferable to cultivation in con-
ventional medium for research application (Ward et al., 1999).
Hybridomas cultured in vitro have in some cases been shown to
produce alternatively glycosylated IgGs relative to those produced
by hybridomas in vivo, affecting their antigen-binding capacities
(Ward et al., 1999). Thus, it may be important to investigate
glycosylation patterns when going from in vitro to in vivo.
Although hybridomas have historically been used extensively
for expression of antibodies within many fields, these cell lines
have several restraints for upscaling. These restraints include
poorly defined nutrient needs of these cell types, accumulation of
toxic metabolites, high oxygen demand, and fragility of the cells
(Randerson, 1985). The problem of chromosomal instability is also
inherent to long-term expression in many cell lines, such as hy-
bridomas, non-secreting murine myeloma (NS0) cells, and human
embryonic kidney (HEK) cells, and overgrowth by nonproducing
cells constitutes another potential problem (Randerson, 1985).Fig. 8. Schematic representation of three different CHO cells expressing three
different glycosylated IgGs. The mammalian cell line contains the necessary cellular
components to produce properly folded and glycosylated IgGs. It has been proposed
that co-culturing such cell lines could be used for the production of recombinant
antivenom based on oligoclonal mixtures of (human) IgGs (Laustsen et al., 2017).6.6. Organisms well suited for large-scale production of antibodies
and antibody fragments
Antibodies and antibody fragments are the fastest growing class
of biopharmaceuticals (Pucca et al., 2011a,b). Most of the organisms
described above are suited for R&D purposes, but have their limi-
tations when it comes to large-scale production. These limitations
include the propensity for producing endotoxins and the restricted
number of formats that can be produced in E. coli, and the low cost-
efficiency and difficulty of upscaling for hybridoma cell lines.
From a quantitative perspective, microbial cell lines, and E. coli
lines in particular, are responsible for the production of the ma-
jority of approved biotherapeutics (Walsh, 2014). However, they are
not responsible for the production of the majority of approved
therapeutic antibodies, which may be due to the inability of mi-
crobial cell lines to provide correct human glycosylation of anti-
bodies (Ecker et al., 2015; Walsh, 2014). Furthermore, microbial cell
lines often attain low yields due to incorrect folding and formation
of aggregates (Chadd and Chamow, 2001). Another disadvantage of
E. coli and other gram-negative bacteria is that they produce en-
dotoxins, which may compromise safety, if they are not properly
removed. While efforts have been made to produce endotoxin-free
E. coli strains for recombinant protein production (Mamat et al.,
2015), no antibodies produced in E. coli have been approved by
the Food and Drug Administration (FDA) or European Medicines
Agency (EMA) since 2009 and 2008, respectively (ACTIP, 2017).
For production of therapeutic antibodies, mammalian cell lines
are often chosen as the expression organism (Berlec and Strukelj,
2013; Wurm, 2004). Mammalian cell lines were responsible forproduction of 95% of approved therapeutic antibodies in 2013
(J€ager et al., 2013) and for the production of 29 out of 30 (96.7%)
approved therapeutic antibodies in 2014 (Walsh, 2014). By com-
parison, E. coli was only responsible for the production of one of
these antibodies in 2014 (Walsh, 2014). One of the popular
mammalian expression hosts for therapeutic proteins is the Chi-
nese Hamster Ovary (CHO) cell. In 2014, CHO cells alone were
responsible for the production of 35.5% of all approved bio-
therapeutics (Walsh, 2014). Although CHO cells are the most
commonly used mammalian cell lines for IgG production, other cell
lines (e.g. NS0, HEK, and hybridoma lines) are also used (Chadd and
Chamow, 2001; Frenzel et al., 2013). Fig. 8 shows a schematic
representation of mammalian (CHO) cell production of IgGs.
Finally, antibodies have also been expressed in other gram-
negative bacteria (in addition to E. coli), gram-positive bacteria,
various yeast strains, fungi, protozoa, insect cells, additional
mammalian cell lines, transgenic plants, and even transgenic ani-
mals (Chadd and Chamow, 2001; Frenzel et al., 2013). Recently, a
recombinant antivenom made in transgenic plants expressing
various camelid antibodies against toxins of the venom of Bothrops
asper was described (Julve Parre~no et al., 2017). Several of the
aforementioned production hosts are in use for large-scale pro-
duction of biotherapeutics (Walsh, 2014), while others are still in
the process of procedure optimization for future large-scale pro-
duction. Given their regulatory success and the efforts put into
strain development and genetic engineering in other fields, it
seems likely, though, that the CHO cell will be the main expression
organism for antibodies in most therapeutic areas e particularly
full IgGs.6.7. Practical considerations for production of recombinant
antivenoms
In addition to production cost, factors to consider when
choosing a manufacturing strategy for (mixtures of) antibodies and
antibody fragments for recombinant antivenoms, include i) the
therapeutic benefits of the specific antibody format (different for-
mats have different PK-PD and are suitable for different purposes),
ii) the importance of (proper) glycosylation, iii) ease of purification,
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for development of production strains, such as CRISPR/Cas systems
(clustered regularly interspaced short palindromic repeats).
Considering these factors, CHO cells or other mammalian cells may
possibly be the best choice for large-scale production of recombi-
nant antivenoms based onmore complex antibody formats, such as
IgG (Walsh, 2014; Wright and Morrison, 1997). In regards to cost of
treatment, it has been suggested that using CHO cells for oligo-
clonal expression of mixtures of recombinant human IgGs could
provide an entire treatment against a typical snakebite envenom-
ing for as little as USD 30e350 (Laustsen et al., 2017, 2016b). This
compares favourably with prices described by Harrison et al., who
report a current market price of an antivenomvial in Kenya ranging
from USD 47.9 to USD 315 (depending on the product), considering
that the treatment of a snakebite case usually requires several vials
(Harrison et al., 2017).7. Targeting toxins of different toxicokinetic profiles and sites
of action
Animal venoms contain cocktails of toxins with a wide range of
biological activities and variable toxicokinetic profiles. Some toxins,
like elapid and scorpion neurotoxins, are low molecular mass
proteins with a large volume of distribution, which allows them to
rapidly reach systemic distribution and access extravascular targets
in the peripheral nervous system (Fig.7D) . Other toxins, such as
high molecular mass metalloproteinases and serine proteinases,
have a lower volume of distribution, and many of them act sys-
temically within the vasculature, generating hemorrhage and
coagulation disorders. Still, some toxins, particularly PLA2s and
metalloproteinases, generate local tissue damage at the site of in-
jection before reaching a systemic distribution. Other venomous
animals that cause local tissue damage include brown spiders
(Loxosceles spp.), whose venom can induce dermonecrotic lesions,
although systemic manifestations are also observed, including
acute kidney injury (Chaim et al., 2006). Thus, these different tox-
icokinetic scenarios and the consequent profile of toxicity associ-
ated with the various types of toxins demand a detailed
consideration when designing the most effective antibody format
for neutralization. Locally acting toxins are possibly better
neutralized by Fabs, scFvs, or VHHs, as these fragments better reach
and neutralize toxins in deep tissue compartments compared to
IgGs (Fig. 7D), which largely remain within blood vessels. Unfor-
tunately, biodistribution studies involving these fragments and
their use as antivenoms are scarce. However, other studies
involving anti-tumor antibodies have already demonstrated their
rapid and efficient tissue penetration, in which scFvs exhibited fast
and high penetration in the tumor mass, while Fabs demonstrated
intermediate tissue penetration in comparison to IgGs (Yokota
et al., 1992). In contrast, an in vivo study using mice envenomed
with B. asper venom, demonstrated that IgG and F(ab’)2 were in fact
capable of reachingmuscle tissue, although the researchers pointed
out that the observed antibody accumulation could be a result of
venom-induced microvascular alterations, which could increase
the antibodies extravasation (Leon et al., 2001). Interestingly, no
differences in the ability to neutralize local tissue damage between
IgG, F(ab’)2, and Fab antivenoms were observed, probably owing to
the effects of tissue damage on antivenom PK (Leon et al., 2000,
1997). Thus, antivenom PK is affected by the pathological changes
induced by venoms in the tissues, and this must be considered
when discussing the best antibody format for a given type of
envenoming.
Systemically acting toxins are known to induce systemic toxic
effects, including neuromuscular blockade, bleeding,coagulopathies, acute kidney injury, and cardiovascular shock,
among others (Gutierrez et al., 2017a). Neurotoxins represent a
relevant example, since they need to reach extravascular targets in
the peripheral nervous system to exert their actions. Venoms from
scorpions, spiders and elapid snakes are rich sources of such neu-
rotoxins (Del Brutto, 2013; Escoubas et al., 2000; Kini and Doley,
2010; Laustsen et al., 2016a, 2016c). The best antibody format to
treat systemically acting toxins may be one that enables rapid
diffusion to the tissues to bind and neutralize toxins that have
reached systemic tissue targets (see section 3). On the other hand,
the long half-life of the IgG format provides prolonged protection
from toxins remaining in the circulatory system, such as high mo-
lecular mass metalloproteinases and serine proteinases, or toxins
escaping the bite site at late stages of envenoming, which is
beneficial in cases where toxins leak from the bite wound over the
course of days. In these circumstances, the prolonged half-life of
IgGs ensures that toxins remaining in the circulatory system or
getting access to the circulatory system at later time periods would
be bound and neutralized. Thus, the optimal antibody format has to
be analyzed on a case by case basis, and it is likely that formulations
that combine high and low molecular mass formats may be the
optimal solution in many cases (Gutierrez et al., 2003).
Toxin neutralization has generally been considered to take place
when a toxin is bound by the variable region of an antibody.
Therefore, antivenoms used in passive immunotherapy are
frequently prepared using Fab/F(ab’)2 formats to limit immunoge-
nicity and the risk of serum sickness. However, with the possibility
of using monoclonal human antibodies, the Fc region has gained
renewed interest (Laustsen et al., 2017; Richard et al., 2013), as it
dramatically increases antibody plasma half-life. The attached Fc
domain also enables the interaction with Fc-receptors found on
immune cells, a feature that is particularly important for clearance
mechanisms. Additionally, from a biophysical perspective, the Fc
domain folds independently and can improve the solubility and
stability of the antibodymolecule (Kontermann, 2011; Nimmerjahn
and Ravetch, 2008). Use of the human Fc domain of novel mono-
clonal toxin-targeting antibodies thus deserves further investiga-
tion e particularly for targeting systemically acting toxins.8. Conclusions and predictions
With the renewed focus on snakebite as a neglected tropical
disease by the WHO (Gutierrez et al., 2017a), a hope emerges that
research efforts within novel envenoming therapies will be inten-
sified. This may not only contribute to the development of a new
generation of antivenoms for treating envenomed snakebite vic-
tims, but it may also pave the way for novel antivenoms against
envenomings by other animals. In the field of antivenom, antibody
technologies have been introduced several decades ago, although
with very limited efforts compared to the fields of oncology,
autoimmune diseases, and infectious diseases. Despite its nascent
state, research within monoclonal antibodies against animal toxins
is thus well-positioned to harness the developments from these
other fields that have made major progress in antibody discovery
technologies, antibody engineering approaches, and antibody
manufacturing.
Based on what is known from the field of antivenom research
itself and general knowledge on monoclonal antibodies, it seems
likely that different antibody formats may be applicable for
different types of envenomings. An urgent need exists for targeting
locally acting toxins with better efficacy within snakebite enve-
nomings (Gutierrez et al., 2017a). However, improvements in
monoclonal human IgG discovery and development also open a
door for improved therapies targeting systemically acting toxins.
A.H. Laustsen et al. / Toxicon 146 (2018) 151e175 169Generally, a trend in antivenom research seems to present itself as a
move away from the use of immunization, hybridoma technology,
and murine antibodies towards phage display technology and hu-
man and camelid antibodies instead (Laustsen, n. d.; Roncolato
et al., 2015). One possible prediction may be that combinatorial
approaches merging (novel) immunization techniques and phage
display may be introduced into the field of antivenom R&D, as
transgenic animals engineered to contain the human antibody
repertoire become more widely available to academia. This would
allow researchers to obtain human antibody mRNA from immu-
nized transgenic animals and use this mRNA to construct affinity
matured fully human antibody phage display libraries. In turn, such
libraries could be employed in a high-throughput fashion for dis-
covery of amultitude of novel toxin-targeting human antibodies. As
auxiliary tools for guiding antivenom development, novel ap-
proaches within determination of antibody cross-reactivity may
accelerate development of novel antivenoms. Particularly prom-
ising technologies include antivenomics, which may provide a
holistic view of the toxin-capturing abilities of antibodies, and
high-density peptide microarray technology, which can provide
amino acid level resolution of epitope-paratope interactions be-
tween toxins and antibodies (Engmark et al., 2017b, 2016). Finally, it
is possible that other display technologies (e.g. mammalian display
(Bowers et al., 2014; Ho and Pastan, 2009)) and novel binding
protein formats, such as DARPins (designed ankyrin repeat pro-
teins) (Rasool et al., 2016; Stumpp et al., 2008), Armadillo repeat
proteins (Varadamsetty et al., 2012), Affitins (Behar et al., 2016;
Correa et al., 2014; Pacheco et al., 2014), Adhirons (Tiede et al.,
2014), Anticalins (Schiefner and Skerra, 2015), and various other
protein scaffolds (Simeon and Chen, 2017) may find their way into
the field of antivenom development.
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